Gujarat Kidney & Superspeciality Limited has released an investor presentation for the second quarter of fiscal year 2027 (Q2 FY27). The presentation outlines the company’s strategic positioning, financial highlights, and operational performance. Key financial figures include Revenue from operations of ₹3,809 Lakhs and EBITDA of ₹1,022 Lakhs for Q2 FY27, demonstrating significant year-on-year growth.
Gujarat Kidney & Superspeciality Limited Investor Presentation Released
Gujarat Kidney & Superspeciality Limited has published its investor presentation for the second quarter of the financial year 2027 (Q2 FY27). The document provides a comprehensive overview of the company’s strategic initiatives, operational achievements, and financial performance. This disclosure is made in accordance with regulatory requirements and aims to keep stakeholders informed about the company’s ongoing developments.
Financial Highlights for Q2 FY27
The presentation highlights robust financial performance in Q2 FY27. Revenue from operations stood at ₹3,809 Lakhs, marking a substantial increase of 195% Year-on-Year (YoY) and 11% Quarter-on-Quarter (QoQ). EBITDA reached ₹1,022 Lakhs, up 99% YoY and 22% QoQ, with an EBITDA margin of 26.8%. Profit After Tax (PAT) was reported at ₹660 Lakhs, showing a significant 129% YoY growth and 24% QoQ increase, with a PAT margin of 17.3%.
Strategic and Operating Highlights
Operationally, the company reported 11 multispeciality hospitals and 10 pharmacies, serving 9 cities across central Gujarat. The total bed capacity is 700, with 690 operational beds. A total of 4,432 procedures were performed, supported by a workforce of 925, including 125 doctors and 450 nurses. The company emphasized its scalable, specialist-led healthcare platform focused on delivering quality, affordable, and patient-centric care.
Expansion and Growth Strategies
Gujarat Kidney & Superspeciality Limited continues its strategy of inorganic expansion, deploying ₹1,669 lakhs towards acquisitions in H1. The company also focuses on operating leverage, with EBITDA margin expansion driven by controlled expenses. Clinical volumes are scaling up, with H1 FY27 already reaching 83% and 82% of FY26 full-year volumes for IPD admissions and OPD visits, respectively. The company maintains a strong, net-cash balance sheet, with net worth of ₹26,364 lakhs and net cash of ₹1,488 lakhs.
Industry Context
The presentation also provides an industry overview, noting India’s healthcare expenditure as a percentage of GDP and its ranking on the Human Development Index. It details the Indian Hospital Sector’s growth, demand drivers such as changing health profiles and increasing geriatric populations, and hospital infrastructure in Gujarat. The company’s integrated business model, focusing on network building, clinical capabilities, and patient journey capture, is also outlined.
Key Takeaways
The investor presentation underscores the company’s consistent growth trajectory, driven by strategic acquisitions, operational efficiencies, and a strong market presence in Gujarat. The focus on expanding tertiary care services and leveraging advanced medical technology positions the company for sustained future growth.
Source: BSE
